LC
BCYC

Lindbrook Capital’s Bicycle Therapeutics BCYC Stock Holding History

Lindbrook Capital’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-500
Closed -$15K – 1853
2021
Q2 		$15K Buy
+500
New +$15.1K ﹤0.01% 879

Other funds holding BCYC

TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

Lindbrook Capital's BCYC Position: Q3 2021 in Review

Lindbrook Capital sold out of Bicycle Therapeutics (BCYC) in Q3 2021, closing a stake of 500 shares — an estimated $15K sold.

Lindbrook Capital first reported a position in BCYC in Q2 2021 and held it in 1 quarter. The position peaked at $15K in Q2 2021. 69 funds tracked by Wall St. Rank hold BCYC as of Q3 2021.

  • Lindbrook Capital reported no remaining Bicycle Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Lindbrook Capital sold 500 Bicycle Therapeutics shares in Q3 2021, an estimated $15K.
  • Lindbrook Capital first reported a position in Bicycle Therapeutics in Q2 2021 and held it in 1 quarter.
  • Lindbrook Capital's Bicycle Therapeutics position peaked at $15K in Q2 2021.
  • 69 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q3 2021.

Based on Lindbrook Capital's 13F filing for Q3 2021, filed 5 Nov 2021.